Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/59523
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

1-Ethyl-2-benzimidazolinone (EBIO) suppresses epileptiform activity in in vitro hippocampus

AutorGarduño, J.; Galván, E.; Fernández de Sevilla, D. CSIC; Buño, Washington CSIC
Fecha de publicación2005
EditorPergamon Press
CitaciónNeuropharmacology 49: 376- 388 (2005)
ResumenCa2+-activated K+ currents with medium (mI AHP) and slow (sIAHP) kinetics, that mediate the post-spike medium and slow after-hyperpolarization (AHP), respectively, play critical roles in regulating neuronal excitability and the spread of epileptiform activity and could provide new therapeutic targets for the management of epileptic patients. We tested if the enhancement of the mI AHP by 1-ethyl-2-benzimidazolinone (EBIO) could suppress epileptiform activity in two in vitro models of epileptogenesis induced in CA3 hippocampal pyramidal neurons by superfusion with 4-AP- and kainate-Mg2+-free solutions. Both interictal- and ictal-like epileptiform activities were reversibly suppressed by EBIO concentrations between 200 μM and 1 mM. EBIO predominantly acted by a strong reduction of excitability via an increase (≈450%) of the mIAHP, without changing the sIAHP. Glutamatergic excitatory synaptic transmission was also diminished (≈50%) by 1 mM EBIO. In contrast, EBIO concentrations <400 μM had no effect on synaptic excitation, consistent with a lesser sensitivity to the drug than the mIAHP. Apamine (100 nM), a toxin that specifically inhibits the mIAHP, rapidly and reversibly antagonized the blocking effects of EBIO on epileptiform activity. Our results suggest that manipulations that enhance the mIAHP may prove adequate in the treatment of epilepsies; they also suggest that an abnormal down regulation of the mIAHP may be a key factor in the genesis of hyperexcitable states. © 2005 Elsevier Ltd. All rights reserved.
URIhttp://hdl.handle.net/10261/59523
DOI10.1016/j.neuropharm.2005.03.021
Identificadoresdoi: 10.1016/j.neuropharm.2005.03.021
issn: 0028-3908
Aparece en las colecciones: (IC) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

27
checked on 19-abr-2024

WEB OF SCIENCETM
Citations

26
checked on 21-feb-2024

Page view(s)

278
checked on 24-abr-2024

Download(s)

89
checked on 24-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.